Skip to main content

Neoadjuvant Neuroblastoma ANBL2131

Status: Open to Enrollment
Email us to enroll

Study details

View study details on clinicaltrials.gov.

Locations

  • Sacramento

Clinical trial FAQs

Information for patients and study volunteers, including frequently asked questions.

A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma

Sandra K Baril, M.D.
Sandra K Baril, M.D.
Principal investigator
View profile

Sub-Investigators

Saunders C Hsu, M.D., MPH, Rachel Bito, M.D., Janice K Ryu, M.D.

Email us to enroll

Related clinical trials

View all clinical trials
  • Clinical trial

    Adjuvant Astrocytomas Grade 3 A072301

    Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination With the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas

    Status: Open to Enrollment

  • Clinical trial

    Metastasis Brain NEO212-01

    An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors

    Status: Open to Enrollment

  • Clinical trial

    Recurrent Glioblastoma SC9-GBM-03

    A Randomized, Open-label, Multicentric, Two-arm Pivotal Trial of SonoCloud-9 Combined With Carboplatin (CBDCA) vs Standard of Care Lomustine (CCNU) or Temozolomide (TMZ) in Patients Undergoing Planned Resection for First Recurrence Glioblastoma.

    Status: Open to Enrollment

  • Clinical trial

    Recurrent or Progressive IDH1 Mutated Glioma NEO100-01

    An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation

    Status: Open to Enrollment

  • Clinical trial

    Residual, Progressive or Recurrent Grade II or III Meningioma NEO100-02

    An Open-Label, Phase 2 Study of NEO100 in Participants With Residual, Progressive or Recurrent High-Grade Meningioma

    Status: Open to Enrollment

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?